These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 36384100)

  • 1. Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial.
    Leventogiannis K; Kyriazopoulou E; Antonakos N; Kotsaki A; Tsangaris I; Markopoulou D; Grondman I; Rovina N; Theodorou V; Antoniadou E; Koutsodimitropoulos I; Dalekos G; Vlachogianni G; Akinosoglou K; Koulouras V; Komnos A; Kontopoulou T; Prekates A; Koutsoukou A; van der Meer JWM; Dimopoulos G; Kyprianou M; Netea MG; Giamarellos-Bourboulis EJ
    Cell Rep Med; 2022 Nov; 3(11):100817. PubMed ID: 36384100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage Activation-Like Syndrome: A Distinct Entity Leading to Early Death in Sepsis.
    Karakike E; Giamarellos-Bourboulis EJ
    Front Immunol; 2019; 10():55. PubMed ID: 30766533
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ImmunoSep (Personalised Immunotherapy in Sepsis) international double-blind, double-dummy, placebo-controlled randomised clinical trial: study protocol.
    Kotsaki A; Pickkers P; Bauer M; Calandra T; Lupse M; Wiersinga WJ; Meylan S; Bloos F; van der Poll T; Slim MA; van Mourik N; Müller MCA; van Vught L; Vlaar APJ; de Nooijer A; Bakkerus L; Weis S; Antonakos N; Netea MG; Giamarellos-Bourboulis EJ
    BMJ Open; 2022 Dec; 12(12):e067251. PubMed ID: 36600424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients.
    Karakike E; Dalekos GN; Koutsodimitropoulos I; Saridaki M; Pourzitaki C; Papathanakos G; Kotsaki A; Chalvatzis S; Dimakopoulou V; Vechlidis N; Paramythiotou E; Avgoustou C; Ioakeimidou A; Kouriannidi E; Komnos A; Neou E; Rovina N; Stefanatou E; Milionis H; Nikolaidis G; Koutsoukou A; Damoraki G; Dimopoulos G; Zoumpos V; Eugen-Olsen J; Akinosoglou K; Gatselis NK; Koulouras V; Gkeka E; Markou N; Netea MG; Giamarellos-Bourboulis EJ
    J Innate Immun; 2022; 14(3):218-228. PubMed ID: 34852352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage activation-like syndrome: an immunological entity associated with rapid progression to death in sepsis.
    Kyriazopoulou E; Leventogiannis K; Norrby-Teglund A; Dimopoulos G; Pantazi A; Orfanos SE; Rovina N; Tsangaris I; Gkavogianni T; Botsa E; Chassiou E; Kotanidou A; Kontouli C; Chaloulis P; Velissaris D; Savva A; Cullberg JS; Akinosoglou K; Gogos C; Armaganidis A; Giamarellos-Bourboulis EJ;
    BMC Med; 2017 Sep; 15(1):172. PubMed ID: 28918754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utility of monocyte HLA-DR and rationale for therapeutic GM-CSF in sepsis immunoparalysis.
    Joshi I; Carney WP; Rock EP
    Front Immunol; 2023; 14():1130214. PubMed ID: 36825018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying inflammatory phenotypes to target mechanism-specific treatments in sepsis.
    Gómez H; Anderko RR; Carcillo JA
    Cell Rep Med; 2022 Nov; 3(11):100823. PubMed ID: 36384087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring immunomodulation in patients with sepsis.
    Kyriazopoulou E; Giamarellos-Bourboulis EJ
    Expert Rev Mol Diagn; 2021 Jan; 21(1):17-29. PubMed ID: 33183116
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunoparalysis: Clinical and immunological associations in SIRS and severe sepsis patients.
    Papadopoulos P; Pistiki A; Theodorakopoulou M; Christodoulopoulou T; Damoraki G; Goukos D; Briassouli E; Dimopoulou I; Armaganidis A; Nanas S; Briassoulis G; Tsiodras S
    Cytokine; 2017 Apr; 92():83-92. PubMed ID: 28119177
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study.
    Leentjens J; Kox M; Koch RM; Preijers F; Joosten LA; van der Hoeven JG; Netea MG; Pickkers P
    Am J Respir Crit Care Med; 2012 Nov; 186(9):838-45. PubMed ID: 22822024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.
    Shakoory B; Carcillo JA; Chatham WW; Amdur RL; Zhao H; Dinarello CA; Cron RQ; Opal SM
    Crit Care Med; 2016 Feb; 44(2):275-81. PubMed ID: 26584195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of immunoparalysis by recombinant human granulocyte-macrophage colony-stimulating factor in patients with severe sepsis.
    Nierhaus A; Montag B; Timmler N; Frings DP; Gutensohn K; Jung R; Schneider CG; Pothmann W; Brassel AK; Schulte Am Esch J
    Intensive Care Med; 2003 Apr; 29(4):646-51. PubMed ID: 12595977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increases in inflammatory and CD14
    Gainaru G; Papadopoulos A; Tsangaris I; Lada M; Giamarellos-Bourboulis EJ; Pistiki A
    Crit Care; 2018 Mar; 22(1):56. PubMed ID: 29499723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interferon gamma-1b in the treatment of compensatory anti-inflammatory response syndrome. A new approach: proof of principle.
    Kox WJ; Bone RC; Krausch D; Döcke WD; Kox SN; Wauer H; Egerer K; Querner S; Asadullah K; von Baehr R; Volk HD
    Arch Intern Med; 1997 Feb; 157(4):389-93. PubMed ID: 9046890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. THE EUROPEAN SHOCK SOCIETY MEETS THE IMMUNOSEP CONSORTIUM FOR PERSONALIZED SEPSIS TREATMENT.
    Giamarellos-Bourboulis EJ; Dimopoulos G; Flohé S; Kotsaki A; van der Poll T; Skirecki T; Torres A; Netea MG
    Shock; 2023 Mar; 59(3S Suppl 1):21-25. PubMed ID: 36867758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients.
    Srisawat N; Tungsanga S; Lumlertgul N; Komaenthammasophon C; Peerapornratana S; Thamrongsat N; Tiranathanagul K; Praditpornsilpa K; Eiam-Ong S; Tungsanga K; Kellum JA
    Crit Care; 2018 Oct; 22(1):279. PubMed ID: 30367647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Immunoparalysis Was Associated with Poor Prognosis in Elderly Patients with Sepsis: Secondary Analysis of the ETASS Study.
    Pei F; Zhang GR; Zhou LX; Liu JY; Ma G; Kou QY; He ZJ; Chen MY; Nie Y; Wu JF; Guan XD;
    Infect Drug Resist; 2020; 13():2053-2061. PubMed ID: 32636658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of Granulocyte-Macrophage Colony-Stimulating Factor or Influenza Vaccination on HLA-DR, Infection and Delirium Days in Immunosuppressed Surgical Patients: Double Blind, Randomised Controlled Trial.
    Spies C; Luetz A; Lachmann G; Renius M; von Haefen C; Wernecke KD; Bahra M; Schiemann A; Paupers M; Meisel C
    PLoS One; 2015; 10(12):e0144003. PubMed ID: 26641243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial.
    Meisel C; Schefold JC; Pschowski R; Baumann T; Hetzger K; Gregor J; Weber-Carstens S; Hasper D; Keh D; Zuckermann H; Reinke P; Volk HD
    Am J Respir Crit Care Med; 2009 Oct; 180(7):640-8. PubMed ID: 19590022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Machine learning derivation of four computable 24-h pediatric sepsis phenotypes to facilitate enrollment in early personalized anti-inflammatory clinical trials.
    Qin Y; Kernan KF; Fan Z; Park HJ; Kim S; Canna SW; Kellum JA; Berg RA; Wessel D; Pollack MM; Meert K; Hall M; Newth C; Lin JC; Doctor A; Shanley T; Cornell T; Harrison RE; Zuppa AF; Banks R; Reeder RW; Holubkov R; Notterman DA; Michael Dean J; Carcillo JA
    Crit Care; 2022 May; 26(1):128. PubMed ID: 35526000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.